+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Dry Powdered Inhaler Market 2019-2025

  • ID: 4988037
  • Report
  • January 2020
  • Region: China
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Cipla Ltd.
  • Gerresheimer AG
China Dry Powdered Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long-Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

China dry powdered inhaler market is anticipated to grow at a substantial rate of around 3.3% during the forecast period. High level of air pollution and the significant number of smokers in China is boosting the demand for inhalers in the country. Additionally, the rising geriatric population susceptible to asthma and COPD within the country is also driving the demand for inhalers; thereby, leading to the growth of the dry powdered inhaler market in the country. From June 2012 to May 2015, a survey was conducted by the Ministry of Health and Ministry of Science and Technology of China. Around 51,000 citizens participated in the survey with 21,500 men and 29,500 women, according to which, it was estimated that about 100 million adults in 2015 had the problem of COPD in the country. The prevalence is higher in men as compared to women. As per the estimation, there were 68.4 million men and 31.5 million women affected by COPD.

China dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators dry powdered inhalers are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing dry powdered inhalers to cater to a wide range of customers within the Chinese market and across the globe. The major players of the China dry powdered inhaler market include Cipla Ltd., Gerresheimer AG, 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp., Teva Pharmaceuticals Industries Ltd., and others. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in July 2019, Cipla Ltd. announced joint-venture (JV) with China-based Jiangsu Acebright Pharma to make respiratory drugs in China. This JV will allow Cipla to expand its footprints in the country and further strengthen its revenue stream.

Research Methodology

The market study of the China dry powdered inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for dry powdered inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. China Dry Powdered Inhaler Market Research and Analysis by Type
2. China Dry Powdered Inhaler Market Research and Analysis by Application
3. China Dry Powdered Inhaler Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the China dry powdered inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the China dry powdered inhaler market.
  • Insights about market determinants which are stimulating the China dry powdered inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Cipla Ltd.
  • Gerresheimer AG
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. China Dry Powdered Inhaler Market by Type
5.1.1. Preventive Inhaler
5.1.2. Reliever Inhaler
5.1.3. Long Acting Bronchodilators Dry Powdered Inhaler
5.2. China Dry Powdered Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. China Dry Powdered Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Company Profiles
6.1. 3M Co.
6.2. Adherium Ltd.
6.3. Aradigm Corp.
6.4. AstraZeneca PLC
6.5. Boehringer Ingelheim International GmbH
6.6. Cipla Ltd.
6.7. Gerresheimer AG
6.8. GlaxoSmithKline PLC
6.9. Koninklijke Philips N.V.
6.10. Novartis AG
6.11. ResMed Corp.
6.12. Sunovion Pharmaceuticals
6.13. Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 3M Co.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Gerresheimer AG
  • GlaxoSmithKline PLC
  • Koninklijke Philips N.V.
  • Novartis AG
  • ResMed Corp.
  • Sunovion Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown